左心室排出分子が保存された心筋梗塞におけるACE阻害剤または血管新生素受容体阻害剤の長期有効性
Anna B C Humphreys1, Bertil Lindahl2, Anita Berglund1
1Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 17177 Stockholm, Sweden.
European heart journal. Cardiovascular pharmacotherapy
|August 31, 2025
まとめ
アンジオテンシン変換酵素阻害剤 (ACEi) とアンジオテンシン受容体阻害剤 (ARB) は,心筋梗塞と保存されたエジェクション分子を患っている患者に有益ではないようです. この研究では,これらの一般的な心臓薬を服用している患者と服用していない患者で,同様の複合的なアウトカムが見つかりました.
科学分野:
- 心臓病科
- 薬理学について
- 臨床研究
背景:
- アニオテンシン変換酵素阻害剤 (ACEi) とアニオテンシン受容体阻害剤 (ARB) は,左心室排出分数 (LVEF) が減少した心筋梗塞 (MI) の治療法として確立されています.
- MIと保存されたLVEF (≥50%) の患者におけるACEi/ARBの有効性は不明である.
研究 の 目的:
- MIと保存されたLVEFの患者における有害な結果の予防におけるACEi/ARBの有効性を調査する.
- この特定の患者集団において,ACEi/ARBが有意な利益をもたらすかどうかを判断する.
主な方法:
- スウェーデンのヘルスケア・レジストリを使用した標的試験のエミュレーション (2010年9月 - 2021年6月)
- MIとLVEF ≥50%を有する75歳未満の個人を含む.
- 治療の意図とプロトコルの効果を推定するために混同調整に使用される逆確率の重み.
主要な成果:
- 合計10,697人がACEi/ARBを投与され,4,730人は投与されなかった.
- 複合的なアウトカム (死亡,心筋梗塞,心不全) の推定5年リスクは,グループごとに類似していた (7. 8% vs 8. 1%).
- 調整した分析も同様のリスクを示した (-0.2%のリスク差).
結論:
- 心臓発作と保存されたLVEF患者のACEi/ ARB治療は有意な効果を示さなかった.
- 死亡,心筋梗塞,心不全の複合リスクは,治療群と非治療群の両方で類似していました.
さらに関連する動画
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.4K
09:37Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
28.1K
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:14Myocarditis III: Medical Management
15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
01:25Aortic Regurgitation III: Medical Management
42
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
42